ArticleIrish journal of medical science2026
PI-RADS 2.1 is valid for detecting prostate cancer in bpMRI in an Irish population.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMagnetic resonance imaging (MR) of the prostate is an important part of the diagnostic pathway for patients with suspected prostate cancer. Current practice in many Irish centres is to perform biparametric MRI (bpMRI) incorporating T2- and diffusion-weighted imaging, and interpret it using the latest version of the American College of Radiology Prostate Imaging Reporting and Data System (PI-RADS), version 2.1. No study has yet reported on the use of bp-MRI and PI-RADS 2.1 in the investigation of prostate cancer investigation in the Irish healthcare setting.
aimsWe aimed to review one year of practice at our regional tertiary prostate cancer referral centre and compare diagnostic yield with international standards.
methodsWe identified all patients who had undergone prostate biopsy at our institution in 2023 and extracted pre-biopsy MRI results for each patient, comparing MRI results with biopsy reports.
resultsWe identified 328 patients in the study period who underwent prostate biopsy and pre-biopsy MRI. 182 of these had a pathological diagnosis of clinically significant prostate cancer (csPCa), defined as Gleason score of 7 or higher. Of these, 167 (92%) had a PI-RADS score of 3 or above, meaning at least equivocal for the presence of csPCA. Cancer detection rates were 31%, 54% and 96% for PI-RADS three, four and five lesions respectively. We demonstrated a sensitivity of 92% and specificity of 49% for detection of csPCa, closely aligned with international datasets.
conclusionsThe use and performance of bpMRI and PI-RADS 2.1 at our Irish tertiary urological centre is in line with international datasets. These have a key role in the diagnostic pathway of prostate cancer in Ireland.
Indexed as
Identifiers
42310281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.